George B McDonald1, James W Freston2, James L Boyer3, Laurie D DeLeve4. 1. University of Washington, Seattle, WA. 2. University of Connecticut Health Center, Farmington, CT. 3. Yale University, New Haven, CT. 4. University of Southern California, Los Angeles, CA.
Abstract
Treatment of hematological malignancy with antibody-drug conjugates (ADCs) may cause liver injury. ADCs deliver a toxic moiety into antigen-expressing tumor cells, but may also injure hepatic sinusoids (sinusoidal obstruction syndrome; SOS). We studied patients who received an anti-CD22/calicheamicin conjugate (inotuzumab ozogamicin; InO) to gain insight into mechanisms of sinusoidal injury, given that there are no CD22+ cells in the normal liver, but nonspecific uptake of ADCs by liver sinusoidal endothelial cells (LSECs). Six hundred thirty-eight patients (307 with acute lymphocytic leukemia [ALL], 311 with non-Hodgkin's lymphoma [NHL]) were randomized to either InO or standard chemotherapy (controls). While blinded to treatment assignment, we reviewed all cases with hepatobiliary complications to adjudicate the causes. Frequency of SOS among patients who received InO was 5 of 328 (1.5%), compared to no cases among 310 control patients. Drug-induced liver injury (DILI) developed in 26 (7.9%) InO recipients and 3 (1%) controls. Intrahepatic cholestasis (IHC) was observed in 4.9% of InO recipients and in 5.5% of controls. Subsequent to the randomization study, 113 patients with ALL underwent allogeneic hematopoietic cell transplantation (HCT); frequency of SOS in those previously exposed to InO was 21 of 79 (27%) versus 3 of 34 (9%) in controls. An exploratory multivariate model identified a past history of liver disease and thrombocytopenia before conditioning therapy as dominant risk factors for SOS after transplant. Conclusion: Frequencies of SOS and DILI after inotuzumab ozogamicin treatment were 1.5% and 7.9%, respectively, compared to none and 1% among controls who received standard chemotherapy. These data suggest that ADCs that do not target antigens present in the normal liver have a relatively low frequency of SOS, but a relatively high frequency of DILI.
Treatment of hematological malignancy with antibody-drug conjugates (ADCs) may cause liver injury. ADCs deliver a toxic moiety into antigen-expressing tumor cells, but may also injure hepatic sinusoids (sinusoidal obstruction syndrome; SOS). We studied patientswho received an anti-CD22/calicheamicin conjugate (inotuzumabozogamicin; InO) to gain insight into mechanisms of sinusoidal injury, given that there are no CD22+ cells in the normal liver, but nonspecific uptake of ADCs by liver sinusoidal endothelial cells (LSECs). Six hundred thirty-eight patients (307 with acute lymphocytic leukemia [ALL], 311 with non-Hodgkin's lymphoma [NHL]) were randomized to either InO or standard chemotherapy (controls). While blinded to treatment assignment, we reviewed all cases with hepatobiliary complications to adjudicate the causes. Frequency of SOS among patientswho received InO was 5 of 328 (1.5%), compared to no cases among 310 control patients. Drug-induced liver injury (DILI) developed in 26 (7.9%) InO recipients and 3 (1%) controls. Intrahepatic cholestasis (IHC) was observed in 4.9% of InO recipients and in 5.5% of controls. Subsequent to the randomization study, 113 patients with ALL underwent allogeneic hematopoietic cell transplantation (HCT); frequency of SOS in those previously exposed to InO was 21 of 79 (27%) versus 3 of 34 (9%) in controls. An exploratory multivariate model identified a past history of liver disease and thrombocytopenia before conditioning therapy as dominant risk factors for SOS after transplant. Conclusion: Frequencies of SOS and DILI after inotuzumabozogamicin treatment were 1.5% and 7.9%, respectively, compared to none and 1% among controls who received standard chemotherapy. These data suggest that ADCs that do not target antigens present in the normal liver have a relatively low frequency of SOS, but a relatively high frequency of DILI.
Authors: June M McKoy; Cara Angelotta; Charles L Bennett; Martin S Tallman; Martha Wadleigh; Andrew M Evens; Timothy M Kuzel; Steve M Trifilio; Dennis W Raisch; Jonathan Kell; Daniel J DeAngelo; Francis J Giles Journal: Leuk Res Date: 2006-09-07 Impact factor: 3.156
Authors: Laurie D DeLeve; Yoshiya Ito; Nancy W Bethea; Margaret K McCuskey; Xiangdong Wang; Robert S McCuskey Journal: Am J Physiol Gastrointest Liver Physiol Date: 2003-02-12 Impact factor: 4.052
Authors: V Méresse; O Hartmann; G Vassal; E Benhamou; D Valteau-Couanet; L Brugieres; J Lemerle Journal: Bone Marrow Transplant Date: 1992-08 Impact factor: 5.483
Authors: Marieke G L Elferink; Peter Olinga; Annelies L Draaisma; Marjolijn T Merema; Klaas Nico Faber; Maarten J H Slooff; Dirk K F Meijer; Geny M M Groothuis Journal: Am J Physiol Gastrointest Liver Physiol Date: 2004-06-17 Impact factor: 4.052
Authors: Vaibhav Agrawal; Praveen Ranganath; Kirsten D Ervin; Caitlin A Schmidt; Elizabeth A Cox; Robert P Nelson; Jennifer E Schwartz; Mohammad Abu Zaid; Rafat Abonour; Michael J Robertson; Bryan J Brinda; Shawn P Griffin; Teresa C Thakrar; Sherif S Farag Journal: Bone Marrow Transplant Date: 2020-07-04 Impact factor: 5.483
Authors: Hagop M Kantarjian; Daniel J DeAngelo; Matthias Stelljes; Michaela Liedtke; Wendy Stock; Nicola Gökbuget; Susan M O'Brien; Elias Jabbour; Tao Wang; Jane Liang White; Barbara Sleight; Erik Vandendries; Anjali S Advani Journal: Cancer Date: 2019-03-28 Impact factor: 6.860